Stylus Medicine
MA - CambridgeBiotechnology
Focus: Stylus Medicine is a Cambridge-based biotech founded in 2011 focused on enzymatic gene therapy. The company operates at mid-cap scale (51-200 employees) and is publicly traded.
Profile data last refreshed 1h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
5
Should You Work at Stylus Medicine?
AI assessmentA specialized gene therapy player with public backing, but lack of pipeline visibility and sparse hiring make it a higher-risk career bet than disclosed clinical-stage peers.
Why Work Here
- Specialized focus on enzymatic gene therapy—a differentiated modality with high scientific complexity and talent premium.
- Public company status provides equity upside and operational stability relative to pre-revenue biotech.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Stylus Medicine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.